Oyster Point Pharma Announces Retirement of William J. Link From Board of Directors
17. März 2022 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma to Participate in the Cowen 42nd Annual Health Care Conference
01. März 2022 16:05 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
24. Februar 2022 16:01 ET
|
Oyster Point Pharma, Inc.
FDA Approved TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021TYRVAYA Nasal Spray Net Product Revenue of $1.2 Million in...
Oyster Point Pharma Announces TYRVAYA™ Nasal Spray Now Covered by Express Scripts
22. Februar 2022 07:00 ET
|
Oyster Point Pharma, Inc.
One of the largest pharmacy benefit management (PBM) companies in the United States has added TYRVAYA (varenicline solution) Nasal Spray to National Preferred, Basic and High-Performance Formularies,...
Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022
16. Februar 2022 16:05 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. Januar 2022 17:08 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022
21. Dezember 2021 16:05 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index
15. Dezember 2021 09:26 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference
30. November 2021 19:09 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease
24. November 2021 07:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...